Literature DB >> 27842322

Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer.

Lauren M Hamel1, Louis A Penner, Terrance L Albrecht, Elisabeth Heath, Clement K Gwede, Susan Eggly.   

Abstract

BACKGROUND: Clinical trials that study cancer are essential for testing the safety and effectiveness of promising treatments, but most people with cancer never enroll in a clinical trial - a challenge exemplified in racial and ethnic minorities. Underenrollment of racial and ethnic minorities reduces the generalizability of research findings and represents a disparity in access to high-quality health care.
METHODS: Using a multilevel model as a framework, potential barriers to trial enrollment of racial and ethnic minorities were identified at system, individual, and interpersonal levels. Exactly how each level directly or indirectly contributes to doctor-patient communication was also reviewed. Selected examples of implemented interventions are included to help address these barriers. We then propose our own evidence-based intervention addressing barriers at the individual and interpersonal levels.
RESULTS: Barriers to enrolling a diverse population of patients in clinical trials are complex and multilevel. Interventions focused at each level have been relatively successful, but multilevel interventions have the greatest potential for success.
CONCLUSION: To increase the enrollment of racial and ethnic minorities in clinical trials, future interventions should address barriers at multiple levels.

Entities:  

Mesh:

Year:  2016        PMID: 27842322      PMCID: PMC5131730          DOI: 10.1177/107327481602300404

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  112 in total

1.  Provider roles in the recruitment of underrepresented populations to cancer clinical trials.

Authors:  Mollie W Howerton; M Chris Gibbons; Charles R Baffi; Tiffany L Gary; Gabriel Y Lai; Shari Bolen; Jon Tilburt; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass; Jean G Ford
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

2.  Aversive Racism and Medical Interactions with Black Patients: A Field Study.

Authors:  Louis A Penner; John F Dovidio; Tessa V West; Samuel L Gaertner; Terrance L Albrecht; Rhonda K Dailey; Tsveti Markova
Journal:  J Exp Soc Psychol       Date:  2010-03-01

3.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.

Authors:  Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

4.  Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.

Authors:  Edward L Korn; Boris Freidlin; Margaret Mooney; Jeffrey S Abrams
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

5.  Racial differences in medical mistrust among men diagnosed with prostate cancer.

Authors:  Chanita Hughes Halbert; Benita Weathers; Ernestine Delmoor; Brandon Mahler; James Coyne; Hayley S Thompson; Thomas Ten Have; David Vaughn; S Bruce Malkowicz; David Lee
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

Review 6.  The NCI Community Oncology Research Program: what every clinician needs to know.

Authors:  Worta McCaskill-Stevens; Alan P Lyss; Marge Good; Thomas Marsland; Rogerio Lilenbaum
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

Review 7.  Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?

Authors:  Kat Kwiatkowski; Kathryn Coe; John C Bailar; G Marie Swanson
Journal:  Cancer       Date:  2013-05-14       Impact factor: 6.860

8.  The Experience of Discrimination and Black-White Health Disparities in Medical Care.

Authors:  Louis A Penner; John F Dovidio; Donald Edmondson; Rhonda K Dailey; Tsveti Markova; Terrance L Albrecht; Samuel L Gaertner
Journal:  J Black Psychol       Date:  2009-05-01

9.  Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities.

Authors:  John H Stewart; Alain G Bertoni; Jennifer L Staten; Edward A Levine; Cary P Gross
Journal:  Ann Surg Oncol       Date:  2007-08-08       Impact factor: 5.344

10.  Recruitment of minority and underserved populations in the United States: the Centers for Population Health and Health Disparities experience.

Authors:  Electra D Paskett; Katherine W Reeves; John M McLaughlin; Mira L Katz; Ann Scheck McAlearney; Mack T Ruffin; Chanita Hughes Halbert; Cristina Merete; Faith Davis; Sarah Gehlert
Journal:  Contemp Clin Trials       Date:  2008-07-31       Impact factor: 2.226

View more
  105 in total

Review 1.  Adolescent angst: enrollment on clinical trials.

Authors:  Theresa H M Keegan; Helen M Parsons
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Barriers and facilitators of clinical trial enrollment in a network of community-based pediatric oncology clinics.

Authors:  Carolyn Russo; Linda Stout; Toni House; Victor M Santana
Journal:  Pediatr Blood Cancer       Date:  2019-09-25       Impact factor: 3.167

3.  Connecting Community to Research: A Training Program to Increase Community Engagement in Research.

Authors:  Tracy A Battaglia; Jennifer Pamphile; Sharon Bak; Nikki Spencer; Christine Gunn
Journal:  Prog Community Health Partnersh       Date:  2019

4.  Reasons for Exclusion from a Smoking Cessation Trial: An Analysis by Race/Ethnicity.

Authors:  Monica Webb Hooper; Taghrid Asfar; Marina Unrod; Asha Dorsey; John B Correa; Karen O Brandon; Vani N Simmons; Michael A Antoni; Tulay Koru-Sengul; David J Lee; Thomas H Brandon
Journal:  Ethn Dis       Date:  2019-01-17       Impact factor: 1.847

5.  Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region.

Authors:  Carsten Nieder; Mohsan A Syed; Astrid Dalhaug; Adam Pawinski; Jan Norum
Journal:  Med Oncol       Date:  2017-07-26       Impact factor: 3.064

6.  Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients.

Authors:  Grace C Hillyer; Melissa Beauchemin; Dawn L Hershman; Moshe Kelsen; Frances L Brogan; Rossy Sandoval; Karen M Schmitt; Andria Reyes; Mary Beth Terry; Andrew B Lassman; Gary K Schwartz
Journal:  Clin Trials       Date:  2020-02-03       Impact factor: 2.486

Review 7.  Racial and ethnic disparities in hematologic malignancies.

Authors:  Kedar Kirtane; Stephanie J Lee
Journal:  Blood       Date:  2017-07-19       Impact factor: 22.113

8.  CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism.

Authors:  Casey R Dorr; Rory P Remmel; Amutha Muthusamy; James Fisher; Branden S Moriarity; Kazuto Yasuda; Baolin Wu; Weihua Guan; Erin G Schuetz; William S Oetting; Pamala A Jacobson; Ajay K Israni
Journal:  Drug Metab Dispos       Date:  2017-05-22       Impact factor: 3.922

Review 9.  Project PLACE: Enhancing community and academic partnerships to describe and address health disparities.

Authors:  Nadine J Barrett; Kearston L Ingraham; Kenisha Bethea; Pao Hwa-Lin; Maritza Chirinos; Laura J Fish; Schenita Randolph; Ping Zhang; Peter Le; Demetrius Harvey; Ronald L Godbee; Steven R Patierno
Journal:  Adv Cancer Res       Date:  2020-03-19       Impact factor: 6.242

10.  Impact of COVID-19 on Clinical Research and Inclusion of Diverse Populations.

Authors:  Daniel T Lackland; Catrina Sims-Robinson; Joy N Jones Buie; Jenifer H Voeks
Journal:  Ethn Dis       Date:  2020-07-09       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.